Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8760435 | 0.98 | L3MBTL1 (0.58) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL38651998 | 0.86 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL759605 | 0.83 | L3MBTL1 (0.56) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL8261357 | 0.83 | L3MBTL1 (0.56) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5290793 | 0.82 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL13343071 | 0.82 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL8306711 | 0.81 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL30984209 | 0.79 | L3MBTL1 (0.44) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL3180576 | 0.79 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL27856917 | 0.79 | L3MBTL1 (0.55) | L3MBTL1MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| CN-102083827-A | Thiazolidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2011-06-01 | — | — | CN | claimed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | claimed |
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2010038200-A1 | OXAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-08 | — | — | WO | claimed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | claimed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | claimed |
| CN-101522618-A | 3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | claimed |
| EP-2079690-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | claimed |
| CN-101405270-A | Pyrazoles as 11-beta-HSD-1 | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| CN-122004231-A | Comprising an oxa carfentrazone-ethyl herbicide composition and application thereof | 山东滨农科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122004230-A | Comprising an oxa carfentrazone-ethyl herbicide composition and application thereof | 山东滨农科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-1015107-B | Process for producing pyrimidine or triazine derivative | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1991-12-18 | — | — | CN | disclosed |
| CN-86107113-A | Herbicidal compounds, process for their preparation and their use | — | 1987-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | L3MBTL1 3789/4885MEN1 659/4885KMT2A 1736/4885 |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | L3MBTL1 4253/4885MEN1 956/4885KMT2A 1003/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | L3MBTL1 2164/4885MEN1 2293/4885KMT2A 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.